Results 81 to 90 of about 7,079 (166)

Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy [PDF]

, 2000
Vigabatrin (VGB) has been shown in a number of clinical trials with varying designs to be effective and well-tolerated as both add-on therapy and monotherapy in epilepsy with partial seizures with or without secondary generalization as well as in ...
Guberman, A, the Canadian Vigabatrin Study Group,, Bruni, J   +2 more
core   +1 more source

Seizure-induced apnea causes sudden death independent of cortical spike wave discharge in mouse models of Tuberous Sclerosis Complex

Neurobiology of Disease
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of seizure-related mortality for people with epilepsy (PWE). Current evidence suggests that many cases of SUDEP are due to seizures that produce respiratory arrest, aka seizure-induced ...
Marissa C. Incer, Ian C. Wenker
doaj   +1 more source

Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions

Neuropsychiatric Disease and Treatment, 2023
Avantika Singh,1,* Aristides Hadjinicolaou,1,* Jurriaan M Peters,1 Catherine L Salussolia1,2 1Division of Epilepsy and Neurophysiology, Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA; 2F.M.
Singh A, Hadjinicolaou A, Peters JM, Salussolia CL   +3 more
doaj  

Treatment of refractory complex partial seizures: role of vigabatrin

, 2009
Elizabeth J Waterhouse, Kimberly N Mims, Soundarya N GowdaDepartment of Neurology, Virginia Commonwealth University School of Medicine, Richmond, VA, USAAbstract: Vigabatrin (VGB) is an antiepileptic drug that was designed to inhibit GABA-transaminase ...
Elizabeth J Waterhouse, Soundarya N Gowda, Kimberly N Mims   +2 more
core  

Study of visual field defects in patients with epilepsy receiving Vigabatrin [PDF]

, 2009
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia between 1989 and 1997 for drug resistant, partial epilepsy and has been associated with visual field defects.
Gonzalez, Pedro Antonio
core   +3 more sources

Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21

Frontiers in Pediatrics
BackgroundInfantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin.
Henry Chen, Henry Chen, Adam L. Numis, Adam L. Numis, Renée A. Shellhaas, John R. Mytinger, Debopam Samanta, Rani K. Singh, Rani K. Singh, Shaun A. Hussain, Danielle Takacs, Kelly G. Knupp, Li-Rong Shao, Carl E. Stafstrom   +13 more
doaj   +1 more source

Movement Disorders in Developmental and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Monogenic developmental and epileptic encephalopathies (DEE) frequently feature co‐occurring movement disorders. Gene discovery has expanded epilepsy‐dyskinesia syndromes (EDS) from classic associations such as stereotypies in Rett syndrome to PRRT2‐related infantile seizures with paroxysmal dyskinesia and crouched gait in SCN1A ...
Shekeeb Mohammad, Darius Ebrahimi‐Fakhari, Hugo Morales‐Briceno   +2 more
wiley   +1 more source

Vigabatrin-Induced Seizures in Angelman Syndrome

Pediatric Neurology Briefs, 1998
Four children with Angelman syndrome (AS) showed worsening of seizures after introduction of vigabatrin (VGB), at the University Children’s Hospital, Zurich, Switzerland.
J Gordon Millichap
doaj   +1 more source

Data‐Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño, Shekeeb S. Mohammad, Rajeshwar Reddy Angiti, Velda Han, Michel Tchan, Russell C. Dale, Victor S.C. Fung   +6 more
wiley   +1 more source

Vigabatrin for refractory partial epilepsy

, 2013
Epilepsy is a common neurological condition which affects between 0.5% and 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs.
Hemming, Karla; id_orcid, Hutton, Jane L, Maguire, Melissa J, Marson, Anthony G   +3 more
core   +1 more source